Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Krytantek Ofteno PF
- Development stage
- Preclinical
- Lead developer
- Laboratorios Sophia
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**Krytantek Ofteno PF** is a preservative-free ophthalmic solution containing a fixed triple combination of dorzolamide (2%), timolol (0.5%), and brimonidine (0.2%), developed by Laboratorios Sophia for treating elevated intraocular pressure (IOP) in primary open-angle glaucoma (POAG) and ocular hypertension. It lowers IOP through complementary mechanisms: dorzolamide inhibits carbonic anhydrase to reduce aqueous humor production, timolol blocks beta-adrenergic receptors to decrease aqueous secretion, and brimonidine activates alpha-2 adrenergic receptors to reduce aqueous production while enhancing uveoscleral outflow. Administered as one drop twice daily, it offers improved adherence over separate instillations and has demonstrated non-inferior efficacy, safety, and tolerability compared to similar combinations in clinical studies.[1][7]
- Brand names
- Krytantek Ofteno PFKrytantek PFKrytantek Ofteno
- Other names
- Brimonidine/dorzolamide/timolol
02
Targets
ADRA2A (α2A)CA2 (Carbonic Anhydrase 2)ADRB1 (β1)ADRB2 (β2)
Beyond the preview
Go deeper on Krytantek Ofteno PF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Krytantek Ofteno PF.